Lisanti Capital Growth LLC Has $5.24 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Lisanti Capital Growth LLC lifted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 92.7% during the first quarter, HoldingsChannel reports. The fund owned 89,210 shares of the company’s stock after purchasing an additional 42,905 shares during the quarter. Apellis Pharmaceuticals comprises approximately 1.3% of Lisanti Capital Growth LLC’s holdings, making the stock its 25th biggest position. Lisanti Capital Growth LLC’s holdings in Apellis Pharmaceuticals were worth $5,244,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Sippican Capital Advisors increased its stake in shares of Apellis Pharmaceuticals by 1.1% in the fourth quarter. Sippican Capital Advisors now owns 16,004 shares of the company’s stock worth $958,000 after acquiring an additional 170 shares during the last quarter. Future Financial Wealth Managment LLC bought a new stake in Apellis Pharmaceuticals in the first quarter worth $29,000. Oppenheimer Asset Management Inc. boosted its holdings in Apellis Pharmaceuticals by 8.3% in the first quarter. Oppenheimer Asset Management Inc. now owns 8,694 shares of the company’s stock worth $511,000 after purchasing an additional 664 shares in the last quarter. Treasurer of the State of North Carolina boosted its holdings in Apellis Pharmaceuticals by 2.3% in the fourth quarter. Treasurer of the State of North Carolina now owns 44,820 shares of the company’s stock worth $2,683,000 after purchasing an additional 1,020 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in Apellis Pharmaceuticals in the first quarter worth $89,000. 96.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $39.24, for a total value of $1,451,880.00. Following the completion of the transaction, the director now owns 136,998 shares of the company’s stock, valued at $5,375,801.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $39.24, for a total value of $1,451,880.00. Following the completion of the transaction, the director now owns 136,998 shares of the company’s stock, valued at $5,375,801.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Pascal Deschatelets sold 78,907 shares of the stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $42.35, for a total transaction of $3,341,711.45. Following the completion of the transaction, the insider now directly owns 1,115,983 shares of the company’s stock, valued at approximately $47,261,880.05. The disclosure for this sale can be found here. 6.80% of the stock is owned by corporate insiders.

Apellis Pharmaceuticals Stock Up 1.6 %

Shares of NASDAQ APLS traded up $0.64 during mid-day trading on Friday, hitting $39.53. The company had a trading volume of 1,674,906 shares, compared to its average volume of 1,387,305. The company has a quick ratio of 3.02, a current ratio of 3.77 and a debt-to-equity ratio of 0.35. The business’s 50-day simple moving average is $40.43 and its 200-day simple moving average is $53.43. Apellis Pharmaceuticals, Inc. has a 12 month low of $19.83 and a 12 month high of $87.38.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, meeting the consensus estimate of ($0.54). Apellis Pharmaceuticals had a negative net margin of 79.67% and a negative return on equity of 160.77%. The business had revenue of $172.33 million during the quarter, compared to analysts’ expectations of $163.37 million. During the same quarter last year, the company earned ($1.56) earnings per share. The firm’s revenue was up 284.3% on a year-over-year basis. As a group, research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on APLS. Wedbush decreased their price objective on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Citigroup decreased their price objective on shares of Apellis Pharmaceuticals from $67.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Wells Fargo & Company decreased their price objective on shares of Apellis Pharmaceuticals from $57.00 to $48.00 and set an “equal weight” rating for the company in a report on Thursday, May 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $85.00 price objective on shares of Apellis Pharmaceuticals in a report on Wednesday, May 8th. Finally, UBS Group decreased their price objective on shares of Apellis Pharmaceuticals from $89.00 to $85.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $75.56.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).